Department of Surgical Oncology, Osaka City University Graduate School of Medicine, Osaka 545-8585, Japan.
J Exp Clin Cancer Res. 2010 Feb 24;29(1):15. doi: 10.1186/1756-9966-29-15.
The combination of gemcitabine (GEM) and S-1, an oral 5-fluorouracil (5-FU) derivative, has been shown to be a promising regimen for patients with unresectable pancreatic cancer.
Six patients with advanced pancreatic cancer were enrolled in this pharmacokinetics (PK) study. These patients were treated by oral administration of S-1 30 mg/m2 twice daily for 28 consecutive days, followed by a 14-day rest period and intravenous administration of GEM 800 mg/m2 on days 1, 15 and 29 of each course. The PK parameters of GEM and/or 5-FU after GEM single-administration, S-1 single-administration, and co-administration of GEM with pre-administration of S-1 at 2-h intervals were analyzed.
The maximum concentration (Cmax), the area under the curve from the drug administration to the infinite time (AUCinf), and the elimination half-life (T1/2) of GEM were not significantly different between GEM administration with and without S-1. The Cmax, AUCinf, T1/2, and the time required to reach Cmax (Tmax) were not significantly different between S-1 administration with and without GEM.
There were no interactions between GEM and S-1 regarding plasma PK of GEM and 5-FU.
吉西他滨（GEM）联合替吉奥（S-1），一种口服氟尿嘧啶（5-FU）衍生物，已被证明是一种有前途的治疗不可切除胰腺癌的方案。
本药代动力学（PK）研究纳入了 6 名晚期胰腺癌患者。这些患者接受替吉奥口服治疗，剂量为 30mg/m2，每日 2 次，连续 28 天，然后休息 14 天；在每个疗程的第 1、15 和 29 天，给予静脉注射吉西他滨 800mg/m2。分析吉西他滨单药、替吉奥单药和吉西他滨与替吉奥间隔 2 小时预给药联合用药后吉西他滨和/或 5-FU 的 PK 参数。
吉西他滨单药与吉西他滨联合替吉奥用药时，吉西他滨的最大浓度（Cmax）、从给药到无穷大时间的曲线下面积（AUCinf）和消除半衰期（T1/2）没有显著差异。替吉奥单药与替吉奥联合吉西他滨用药时，Cmax、AUCinf、T1/2 和达到 Cmax 的时间（Tmax）也没有显著差异。
吉西他滨与替吉奥联合用药时，吉西他滨和 5-FU 的血浆 PK 没有相互作用。
